Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model.

Endocrinology | 2013

Recent epidemiological studies provide strong evidence suggesting obesity is a risk factor in several cancers, including thyroid cancer. However, the molecular mechanisms by which obesity increases the risk of thyroid cancer are poorly understood. In this study, we evaluated the effect of diet-induced obesity on thyroid carcinogenesis in a mouse model that spontaneously develops thyroid cancer (Thrb(PV/PV)Pten(+/-) mice). These mice harbor a mutated thyroid hormone receptor-β (denoted as PV) and haplodeficiency of the Pten gene. A high-fat diet (HFD) efficiently induced the obese phenotype in Thrb(PV/PV)Pten(+/-) mice after 15 weeks. Thyroid tumor growth was markedly greater and survival was significantly lower in Thrb(PV/PV)Pten(+/-) mice fed an HFD than in controls fed a low-fat diet (LFD). The HFD increased thyroid tumor cell proliferation by increasing the protein levels of cyclin D1 and phosphorylated retinoblastoma protein to propel cell cycle progression. Histopathological analysis showed that the frequency of anaplasia of thyroid cancer was significantly greater (2.6-fold) in the HFD group than the LFD group. The HFD treatment led to an increase in parametrial/epididymal fat pad and elevated serum leptin levels in Thrb(PV/PV)Pten(+/-) mice. Further molecular analyses indicated that the HFD induced more aggressive pathological changes that were mediated by increased activation of the Janus kinase 2-signaling transducer and activator of transcription 3 (STAT3) signaling pathway and induction of STAT3 target gene expression. Our findings demonstrate that diet-induced obesity exacerbates thyroid cancer progression in Thrb(PV/PV)Pten(+/-) mice and suggest that the STAT3 signaling pathway could be tested as a potential target for the treatment of thyroid cancer.

Pubmed ID: 23748362 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Jak2 (D2E12) XP Rabbit mAb (antibody)

RRID:AB_2128522

This monoclonal targets Jak2 (D2E12) XP Rabbit mAb

View all literature mentions

cyclin E (M-20) (antibody)

RRID:AB_2275345

This polyclonal targets CCNE1

View all literature mentions

Phospho-Rb (Ser780) Antibody (antibody)

RRID:AB_330015

This polyclonal targets Phospho-Rb (Ser780)

View all literature mentions

p44/42 MAPK (Erk1/2) Antibody (antibody)

RRID:AB_330744

This polyclonal targets p44/42 MAPK (Erk1/2)

View all literature mentions

Phospho-Stat-3 (tyr705) (antibody)

RRID:AB_331586

This polyclonal targets Phospho-Stat3 (Tyr705) Antibody detects endogenous levels of Stat3 only when phosphorylated at Tyr705. The antibody does not cross-react with other Stat proteins when phosphorylated on the corresponding tyrosine residue. Does cross-react withPhospho-EGFR

View all literature mentions

Signal Transducer and Activator of Transcription 3 (antibody)

RRID:AB_331588

This unknown targets synthetic peptide corresponding to the sequence of mouse Stat3.

View all literature mentions

cyclin B1 (GNS1) (antibody)

RRID:AB_627338

This monoclonal targets cyclin B1 (GNS1)

View all literature mentions

cyclin D1 (72-13G) (antibody)

RRID:AB_627342

This monoclonal targets cyclin D1

View all literature mentions

Rb (C-15) (antibody)

RRID:AB_632339

This polyclonal targets RB1

View all literature mentions